The European Medicines Agency (EMA) announced on Monday 16 August that it had started a rolling review of a seventh potential treatment for Covid-19 - RoActemra (tocilizumab), an anti-inflammatory drug authorised in the European Union since 2009.
In a statement, the EMA said that if the “rolling review” is successful, the treatment could be extended to adult in-patients with severe Covid-19, “who are already receiving treatment with corticosteroids and require extra oxygen or...